HIV Flashcards
preferred INSTIs for use in pregnancy
RAL or DTG
K65R
tenofovir
Q148R and N155H
integrase inhibitor
Time window for PEP
72 hours
G140S and Q148R
Dolutegravir
Methods to acquire toxoplasmosis
feline feces (cats have to be outdoor eating rodents)
eating rare meat (lamb, beef, pork)
congenital transmission
Definitive diagnosis of CNS too
brain biopsy
CSF PCR
Serum PCR
Preferred therapy for CNS toxo
sulfadiazine, pyrimethamine, leucovorin
TMP-SMX
alternative therapies for CNS toxo
clindamycin plus pyrimethamine
atovaquone plus pyrimethamine
Toxo PPX IgG + and CD4 <100
TMP-SMX
Dapsone-pyrimethamine
Atovaquone pyrimethamine
m haemophilum culture
32C with iron enriched medium
positive PPD for HIV
5 mm
When to start ART after TB treatment started CD4 < 50
2 weeks
when to start ART after TB treatment started CD4 > 50
8 weeks
requirement for TB drug therapy in HIV
must be daily dosed drugs
when to start ART after Mac therapy
within 2 weeks
treatment for dMAC
clarithromycin/azithromycin plus EMB
rifabutin is optional third drug for severe disease
issue with CSF Crypto PCR
can have false negatives, always use CrAg
CSF PCR crypto utility
distinguish between IRIS (PCR negative) and relapse (PCR positive)T
treatment Course of Crypto meningitis
2 weeks induction (LAMB 5-FC)
8 weeks consolidation (Fluc 800 qd)
Maintenance Fluc 200 qd (52 weeks)
when to stop therapy for cryptococcal meningitis
stop after 12 months therapy if
CD4 is greater than 100-150 for more than 3 months
Asymptomatic
VL < 50 copies
utility of monitoring CSF Crag while on therapy
none
when to monitor 5-FC levels
after dose 3 or 5
when to start ART after cryptococcal meningitis
4-6 weeks
when to screen patients for crypto
if CD4 <100
management of positive CrAg
LP and blood cultures
If CSF positive or serum LFA > 640 treat like meningitis
If CSF negative treat with fluconazole 400 mg or 800 mg x 6 months
flucytosine toxicity
marrow suppression
hepatitis
diarrhea
talaromyces treatment
amp or itraconazole
talaromyces seen in
asia
HIV–2 is naturally resistant to which drug classes
NNRTIs
fusion inhibitors
HIV-2 is commonly seen in
west africa
france
spain
india
flower cells
typical of HTLV-1
HTLV-1 commonly seen in
caribbean
australia
HTLV-2 clinical significance
none does not cause disease in humans
T/F HTLV-1 can be transmitted by breastfeeding
true
HTLV-1 CANCER association
Acute T cell leukemia
HTLV-1 infectious syndromes
TB
MAC
Leprosy
PCP
recurrent strongyloides
scabes/norwegian scabies
Associated neuro syndrome with HTLV-1
tropical spastic paraparesis
features of tropical spastic paraparesis
bladder disturbance
hyperreflexia
positive babinski
role of ART in HTLV-1
none
clinical features of CJD
myoclonus and dementia
most common CJD transmission route
spontaneous
which CSF marker is most consistent with CJD
RT-QuIC test
what is the second best marker for CJD
elevated 14-3-3 proteins in CSF
EEG in CJD
periodic sharp waves
EEG findings in variant CJD
none
MRI findings in spontaneous CJD
double hockey stick sign
MR findings in variant CJD
pulvinar sign
bilateral FLAIR hyper intensities seen in the thalamic nuclei
pathology in sCJD
abnormal prion accumulation
pathology in vCJD
florid plaques
dura mater graft association acquiring iatrogenic CJD seen in what country
Japan
ingestion of beef causing CJD seen in which two countries most frequently
UK and France
oral hairy leukoplakia associated with
EBV